Panel Recommends Expanded Mesothelioma Drug Regimen, According to Surviving Mesothelioma

Share Article

A 27-member national network of cancer centers says mesothelioma care could be improved by adding a third drug to standard mesothelioma chemotherapy.

Panel Recommends Revised Mesothelioma Treatment

New Mesothelioma Drug Combo?

The NCCN panel also now recommends bevacizumab/cisplatin/pemetrexed as a first-line therapy option for patients with unresectable MPM...

The National Comprehensive Cancer Network (NCCN) has expanded its recommendation for first-line pleural mesothelioma treatment to include the drug bevacizumab (Avastin). Surviving Mesothelioma has just posted a new article on the revised recommendations. Click here to read it now.

The group, which includes top cancer centers from around the country, cites recent research showing that the antiangiogenesis drug extends mesothelioma survival when administered along with pemetrexed (Alimta) and cisplatin as part of first-line treatment.

“The NCCN panel recommends cisplatin/pemetrexed (category 1) for patients with malignant pleural mesothelioma,” writes David Ettinger, MD, of The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. “The NCCN panel also now recommends bevacizumab/cisplatin/pemetrexed as a first-line therapy option for patients with unresectable MPM who are candidates for bevacizumab.”

Information about the revised recommendations appears in a recent edition of the Journal of the National Comprehensive Cancer Network.

“Surviving Mesothelioma is committed to keeping mesothelioma patients and their families up to date on the very latest recommendations and guidelines related to this devastating cancer,” says Alex Strauss, the site’s Managing Editor. “The bevacizumab option represents the first time mesothelioma chemotherapy has undergone any significant change since pemetrexed (Alimta) was approved in 2004.”

For more information on the revised NCCN guidelines and details on the latest research on bevacizumab, see Three-Drug Combo May Be New Standard-of-Care for Mesothelioma Treatment, now available on the Surviving Mesothelioma website.

Ettinger, DS, “NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016”, July 2016, Journal of the National Comprehensive Cancer Network, pp. 825-836,

For nearly ten years, Surviving Mesothelioma has brought readers the most important and ground-breaking news on the causes, diagnosis and treatment of mesothelioma. All Surviving Mesothelioma news is gathered and reported directly from the peer-reviewed medical literature. Written for patients and their loved ones, Surviving Mesothelioma news helps families make more informed decisions.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michael Ellis
Cancer Monthy
+1 (919) 570-8595
Email >
Follow us on
Visit website